Dr. Reddy's Laboratories approaches its June 1 earnings release with the same stubborn divergence that has defined this entire preview cycle — but the data has shifted under both camps since yesterday's article.
Short interest has pulled back slightly from its Wednesday peak. Shares short eased roughly 0.7% on Thursday to approximately 19.8 million, retreating from the 19.9 million cycle high but still up 21.7% on the week and 30.5% over the month. The ORTEX short score dipped fractionally to 57.1 from 57.3, though it remains near the series high. Critically, availability has recovered further — now at 60.4%, up sharply from the 55.7% reading in yesterday's preview and well above the 31–33% cycle lows of last week. That loosening matters: with roughly one share available for every one-and-a-half borrowed, the lending pool is no longer as congested as it was at the worst of last week's tightening. Cost to borrow has also eased to 0.76%, down from 0.84% at the peak, though it remains elevated against the sub-0.60% levels seen earlier in May.
Options traders have not budged. The put/call ratio held at 0.15 on Friday — almost identical to the 0.14–0.15 range that has anchored call-dominated flow since mid-May. That is well below the 20-day average of 0.41 and nowhere near the PCR readings above 1.10 that prevailed in early May. Call demand continues to dominate by a wide margin, leaving the two positioning camps as far apart as they have been throughout this preview series.
The analyst record is stale and cannot be relied upon here — the most recent confirmed price target is from HSBC in June 2025, which placed the stock at $16.90, well above the current $13.63. The valuation picture is more current: the PE multiple has compressed about 4% over the past month to 22.7x, with the EV/EBITDA ratio sitting at 13.8x. The dividend factor score ranks in the 90th percentile — notable for a generic pharma name — though dividend history here is denominated in INR and the last declared dividend dates to 2022. Founder-linked holders Kallam Reddy and Gunupati Prasad together hold more than 26% of shares outstanding with no recent change, providing an unusually stable institutional anchor.
Monday's print is therefore a direct test of which camp has read the margin and revenue trajectory correctly — the call buyers betting on a catalyst, or the shorts who have spent the past month building the largest position of this entire preview cycle.
See the live data behind this article on ORTEX.
Open RDY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
